Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers

Caroline Holm Nørgaard; Sarah Friedrich; Charlotte Thim Hansen; Thomas Gerds; Clive Ballard; Daniel Vega Møller; Lotte Bjerre Knudsen; Kajsa Kvist; Bernard Zinman; Ellen Holm; Christian Torp-Pedersen; Lina Steinrud Mørch

doi:10.1002/trc2.12268

Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers

Caroline Holm Nørgaard, Sarah Friedrich, Charlotte Thim Hansen, Thomas Gerds, Clive Ballard, Daniel Vega Møller, Lotte Bjerre Knudsen, Kajsa Kvist, Bernard Zinman, Ellen Holm, Christian Torp-Pedersen, Lina Steinrud Mørch

Abstrakt

Introduction: People with type 2 diabetes have increased risk of dementia. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease; a key unanswered question is whether they reduce dementia incidence in people with type 2 diabetes.

Methods: We assessed exposure to GLP-1 RAs in patients with type 2 diabetes and subsequent diagnosis of dementia in two large data sources with long-term follow-up: pooled data from three randomized double-blind placebo-controlled cardiovascular outcome trials (15,820 patients) and a nationwide Danish registry-based cohort (120,054 patients).

Results: Dementia rate was lower both in patients randomized to GLP-1 RAs versus placebo (hazard ratio [HR]: 0.47 (95% confidence interval [CI]: 0.25-0.86) and in the nationwide cohort (HR: 0.89; 95% CI: 0.86-0.93 with yearly increased exposure to GLP-1 RAs).

Discussion: Treatment with GLP-1 RAs may provide a new opportunity to reduce the incidence of dementia in patients with type 2 diabetes.

Originalsprog	Engelsk
Artikelnummer	e12268
Tidsskrift	Alzheimer's & dementia (New York, N. Y.)
Vol/bind	8
Udgave nummer	1
Sider (fra-til)	e12268
ISSN	2352-8737
DOI	https://doi.org/10.1002/trc2.12268
Status	Udgivet - 2022

Adgang til dokumentet

10.1002/trc2.12268

Andre filer og links

Link to publication in Scopus

Citationsformater

Nørgaard, C. H., Friedrich, S., Hansen, C. T., Gerds, T., Ballard, C., Møller, D. V., Knudsen, L. B., Kvist, K., Zinman, B., Holm, E., Torp-Pedersen, C., & Mørch, L. S. (2022). Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimer's & dementia (New York, N. Y.), 8(1), e12268. [e12268]. https://doi.org/10.1002/trc2.12268

Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia : Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. / Nørgaard, Caroline Holm; Friedrich, Sarah; Hansen, Charlotte Thim et al.

I: Alzheimer's & dementia (New York, N. Y.), Bind 8, Nr. 1, e12268, 2022, s. e12268.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Nørgaard, CH, Friedrich, S, Hansen, CT, Gerds, T, Ballard, C, Møller, DV, Knudsen, LB, Kvist, K, Zinman, B, Holm, E, Torp-Pedersen, C & Mørch, LS 2022, 'Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers', Alzheimer's & dementia (New York, N. Y.), bind 8, nr. 1, e12268, s. e12268. https://doi.org/10.1002/trc2.12268

Nørgaard CH, Friedrich S, Hansen CT, Gerds T, Ballard C, Møller DV et al. Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimer's & dementia (New York, N. Y.). 2022;8(1):e12268. e12268. https://doi.org/10.1002/trc2.12268

@article{037596a414d14ca1a86e438797d770d6,

title = "Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers",

abstract = "Introduction: People with type 2 diabetes have increased risk of dementia. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease; a key unanswered question is whether they reduce dementia incidence in people with type 2 diabetes.Methods: We assessed exposure to GLP-1 RAs in patients with type 2 diabetes and subsequent diagnosis of dementia in two large data sources with long-term follow-up: pooled data from three randomized double-blind placebo-controlled cardiovascular outcome trials (15,820 patients) and a nationwide Danish registry-based cohort (120,054 patients).Results: Dementia rate was lower both in patients randomized to GLP-1 RAs versus placebo (hazard ratio [HR]: 0.47 (95% confidence interval [CI]: 0.25-0.86) and in the nationwide cohort (HR: 0.89; 95% CI: 0.86-0.93 with yearly increased exposure to GLP-1 RAs).Discussion: Treatment with GLP-1 RAs may provide a new opportunity to reduce the incidence of dementia in patients with type 2 diabetes.",

author = "N{\o}rgaard, {Caroline Holm} and Sarah Friedrich and Hansen, {Charlotte Thim} and Thomas Gerds and Clive Ballard and M{\o}ller, {Daniel Vega} and Knudsen, {Lotte Bjerre} and Kajsa Kvist and Bernard Zinman and Ellen Holm and Christian Torp-Pedersen and M{\o}rch, {Lina Steinrud}",

note = "{\textcopyright} 2022 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.",

year = "2022",

doi = "10.1002/trc2.12268",

language = "English",

volume = "8",

pages = "e12268",

journal = "Alzheimer's & Dementia: Translational Research & Clinical Interventions",

issn = "2352-8737",

publisher = "Elsevier Inc",

number = "1",

}

TY - JOUR

T1 - Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia

T2 - Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers

AU - Nørgaard, Caroline Holm

AU - Friedrich, Sarah

AU - Hansen, Charlotte Thim

AU - Gerds, Thomas

AU - Ballard, Clive

AU - Møller, Daniel Vega

AU - Knudsen, Lotte Bjerre

AU - Kvist, Kajsa

AU - Zinman, Bernard

AU - Holm, Ellen

AU - Torp-Pedersen, Christian

AU - Mørch, Lina Steinrud

PY - 2022

Y1 - 2022

N2 - Introduction: People with type 2 diabetes have increased risk of dementia. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease; a key unanswered question is whether they reduce dementia incidence in people with type 2 diabetes.Methods: We assessed exposure to GLP-1 RAs in patients with type 2 diabetes and subsequent diagnosis of dementia in two large data sources with long-term follow-up: pooled data from three randomized double-blind placebo-controlled cardiovascular outcome trials (15,820 patients) and a nationwide Danish registry-based cohort (120,054 patients).Results: Dementia rate was lower both in patients randomized to GLP-1 RAs versus placebo (hazard ratio [HR]: 0.47 (95% confidence interval [CI]: 0.25-0.86) and in the nationwide cohort (HR: 0.89; 95% CI: 0.86-0.93 with yearly increased exposure to GLP-1 RAs).Discussion: Treatment with GLP-1 RAs may provide a new opportunity to reduce the incidence of dementia in patients with type 2 diabetes.

AB - Introduction: People with type 2 diabetes have increased risk of dementia. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease; a key unanswered question is whether they reduce dementia incidence in people with type 2 diabetes.Methods: We assessed exposure to GLP-1 RAs in patients with type 2 diabetes and subsequent diagnosis of dementia in two large data sources with long-term follow-up: pooled data from three randomized double-blind placebo-controlled cardiovascular outcome trials (15,820 patients) and a nationwide Danish registry-based cohort (120,054 patients).Results: Dementia rate was lower both in patients randomized to GLP-1 RAs versus placebo (hazard ratio [HR]: 0.47 (95% confidence interval [CI]: 0.25-0.86) and in the nationwide cohort (HR: 0.89; 95% CI: 0.86-0.93 with yearly increased exposure to GLP-1 RAs).Discussion: Treatment with GLP-1 RAs may provide a new opportunity to reduce the incidence of dementia in patients with type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=85131062735&partnerID=8YFLogxK

U2 - 10.1002/trc2.12268

DO - 10.1002/trc2.12268

M3 - Journal article

C2 - 35229024

VL - 8

SP - e12268

JO - Alzheimer's & Dementia: Translational Research & Clinical Interventions

JF - Alzheimer's & Dementia: Translational Research & Clinical Interventions

SN - 2352-8737

IS - 1

M1 - e12268

ER -

Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers

Abstrakt

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater